Independent directory Public ClinicalTrials.gov records United States
Location Directory

Clinical trials in Houston, Texas

This page shows live ClinicalTrials.gov search results for Houston, Texas, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 3:35 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
22507
Shown on this page
12
Current sort
Recently updated
Location scope
Houston, TX
Filters apply within this location only.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this location

These controls apply only within Houston, Texas. Default order is Recently updated. Use recruitment status if you want to focus on actively recruiting studies in this location.

Reset location filters
Clear filters
Showing 445–456 of 22,507 matching trials in Houston, TX.
Live ClinicalTrials.gov results.
Local directory summary panels are hidden while filters are applied so the page stays focused on the filtered live results.

Institutions in Houston

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Live official records

Open in full search
Conditions
Atrial Fibrillation
Interventions
Milvexian, Apixaban, Placebo, Apixaban Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
20,284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
216
States / cities
Alexander City, Alabama • Birmingham, Alabama • Dothan, Alabama + 182 more
Conditions
Depressive Disorder, Major
Interventions
Esketamine, Midazolam, Oral Placebo, Intranasal Placebo
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
12 Years to 17 Years
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
12
States / cities
Birmingham, Alabama • New Haven, Connecticut • Washington D.C., District of Columbia + 9 more
Conditions
Prostate Cancer
Interventions
Arm A: 177Lu rhPSMA-10.1, Arm B: 177Lu rhPSMA-10.1 plus Degarelix
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Houston, Texas
Active, not recruiting Not applicable Interventional

Memory Gel and Shape Combined Cohort

NCT02919592
Conditions
Primary Breast Augmentation, Primary Breast Reconstruction, Revision Breast Augmentation, Revision Breast Reconstruction
Interventions
MemoryShape® Breast Implants, MemoryGel® Breast Implants, Other Aesthetic Surgery
Device · Procedure
Lead sponsor
Mentor Worldwide, LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
3,603 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2031
U.S. locations
78
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Gilbert, Arizona + 64 more
Conditions
HIV-1
Interventions
PGT121.414.LS, VRC07-523LS
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 72 Hours
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
13
States / cities
Los Angeles, California • Aurora, Colorado • Jacksonville, Florida + 7 more
Conditions
Psilocybin, Neuropathy
Interventions
Psilocybin (drug), Standard of Care (SOC)
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Houston, Texas
Active, not recruiting No phase listed Observational

Psoriasis Longitudinal Assessment and Registry

NCT00508547
Conditions
Psoriasis
Interventions
Not listed
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
21,190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2030
U.S. locations
167
States / cities
Birmingham, Alabama • Florence, Alabama • Huntsville, Alabama + 164 more
Conditions
Advanced Small Intestine Cancer, Appendiceal Cancers
Interventions
Patients will be treated with NALIRIFOX (liposomal irinotecan 50 mg/m2 + 5-FU 2400 mg/m2 + LV 400 mg/m2 + oxaliplatin 60 mg/m2, IV) every 2 weeks for 12 months
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Houston, Texas
Conditions
Atrial Fibrillation
Interventions
AFSW Guided DOAC, Continuous DOAC therapy
Device · Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
22 Years to 85 Years
Enrollment
5,350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
93
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 68 more
Conditions
Ulcerative Colitis
Interventions
Not listed
Lead sponsor
Janssen Biotech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
535 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
16
States / cities
Murrieta, California • Rialto, California • Ventura, California + 13 more
Conditions
Non-Small Cell Lung Cancer, ICI-refractory
Interventions
SAR445877
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Houston, Texas
Conditions
Recurrent Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v7, Unresectable Hepatocellular Carcinoma
Interventions
Proton Therapy, Photon Therapy
Radiation
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2031
U.S. locations
27
States / cities
Atlanta, Georgia • Warrenville, Illinois • Baltimore, Maryland + 18 more